Arrowstreet Capital
DNTH icon

Arrowstreet Capital’s Dianthus Therapeutics DNTH Stock Holding History

Arrowstreet Capital’s Portfolio DNTH Stock Details DNTH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q4 		– Sell
-1,679
Closed -$183K – 2338
2020
Q3 		$183K Buy
1,679
+860
+105% +$102K ﹤0.01% 2215
2020
Q2 		$98K Buy
+819
New +$115K ﹤0.01% 2224

Other funds holding DNTH

TGI
TRV GP IV Boston, Massachusetts $267M AUM 965.83% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $8.34B AUM 46.58% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return
ACM
Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return
BL
Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return

Arrowstreet Capital's DNTH Position: Q4 2020 in Review

Arrowstreet Capital sold out of Dianthus Therapeutics (DNTH) in Q4 2020, closing a stake of 1,679 shares — an estimated $183K sold.

Arrowstreet Capital first reported a position in DNTH in Q2 2020 and held it in 2 quarters. The position peaked at $183K in Q3 2020. 92 funds tracked by Wall St. Rank hold DNTH as of Q4 2020.

  • Arrowstreet Capital reported no remaining Dianthus Therapeutics position as of Q4 2020 after selling out during the quarter.
  • Arrowstreet Capital sold 1,679 Dianthus Therapeutics shares in Q4 2020, an estimated $183K.
  • Arrowstreet Capital first reported a position in Dianthus Therapeutics in Q2 2020 and held it in 2 quarters.
  • Arrowstreet Capital's Dianthus Therapeutics position peaked at $183K in Q3 2020.
  • 92 funds tracked by Wall St. Rank held Dianthus Therapeutics as of Q4 2020.

Based on Arrowstreet Capital's 13F filing for Q4 2020, filed 12 Feb 2021.